Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells

Background: Immune cells recognize tumor antigens presented on major histocompatibility complex class I (MHC-I) molecule. Increase of MHC-I molecular expression makes tumor cells more susceptible to lysis by immune cells. Methods: Tumor lysate vaccine was prepared to damage glioma cells including cell lines and primary cultured cells from surgical samples. The enhanced effect of histone deacetylase inhibitors (HDACi) to tumor lysate vaccine was observed. The expressions of MHC-I pathway molecules were detected by flow cytometry and western blot after HDACi treatment. Cell apoptosis and cell lysis were measured following blocking cytotoxic T lymphocyte (CTL) pathway. Tumor size and mice survival were analyzed in combinative treatment with HDACi and tumor lysate. Results: HDACi up-regulated the expressions of MHC-I pathway molecules, and enhanced the recognition and killing of immune cells, which was activated by tumor lysate. Activated antigen specific immune responses regulated CTL activity, and HDACi promoted immune response through cytotoxic effect of CTL. Anti-tumor effect of tumor lysate pulse immunogenicity in vivo was elevated by HDACi due to up-regulation of antigen presentation. Conclusions: Our study showed that HDACi enhanced recognition of glioma cell by immune cells and sensitivity of tumor immunotherapy, and improved the anti-tumor effect of tumor lysate vaccine through activating CTL immune response. These pharmacological molecular mechanisms of increasing immune recognition suggest that epigenetic modulation is a promising strategy for sensitizing immunotherapy for glioma treatment.

[1]  Lieping Chen,et al.  B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction , 2018, Proceedings of the National Academy of Sciences.

[2]  Yingying Liu,et al.  HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway. , 2018, Cancer letters.

[3]  P. Munster,et al.  HDAC inhibition potentiates immunotherapy in triple negative breast cancer , 2017, Oncotarget.

[4]  A. Levine,et al.  A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy , 2017, Nature.

[5]  B. Seliger,et al.  Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling. , 2017, Cancer research.

[6]  T. Cloughesy,et al.  Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma , 2017, Neuro-oncology.

[7]  Edward James,et al.  Antigen processing and immune regulation in the response to tumours , 2017, Immunology.

[8]  P. Munster,et al.  Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. , 2016, Immunotherapy.

[9]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[10]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[11]  R. Johnstone,et al.  The anticancer effects of HDAC inhibitors require the immune system , 2014, Oncoimmunology.

[12]  L. Terracciano,et al.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. , 2014, Neoplasia.

[13]  Menna E. Jones,et al.  Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer , 2013, Proceedings of the National Academy of Sciences.

[14]  B. Seliger,et al.  The role of classical and non-classical HLA class I antigens in human tumors. , 2012, Seminars in cancer biology.

[15]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[16]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[17]  S. H. van der Burg,et al.  Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires , 2011, European journal of immunology.

[18]  R. Gopaul,et al.  Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. , 2008, Cancer research.

[19]  J. Bubeník,et al.  Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen‐processing machinery components in a murine model for human papilloma virus 16‐associated tumours , 2007, Immunology.

[20]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[21]  H. Kuipers,et al.  Transcriptional regulation of antigen presentation. , 2004, Current opinion in immunology.

[22]  S. Sheen-Chen,et al.  An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. , 1994, Surgery.